NSAID用于高血压、心血管、肾脏或胃肠共病患者的联合推荐
该推荐由APAGE/APLAR/APSDE/APSH/APSN/PoA联合制定,基于2018年1月前发表的随机对照试验和观察性研究共329篇文献,针对高血压、心血管、肾脏或胃肠共病患者安全处方NSAID提出多学科推荐。核心建议包括:高风险患者尽量避免NSAID,无法避免时优选萘普生或塞来昔布,并根据消化道溃疡风险选择PPI或选择性COX-2抑制剂,同时监测血压和肾功能。
要点
- 治疗抵抗性高血压、高心血管风险及严重CKD患者应尽可能避免NSAID。
- 高心血管风险者若需NSAID,优选萘普生或塞来昔布。
- 根据消化道溃疡风险选择非选择性NSAID+PPI或选择性COX-2抑制剂±PPI。
核心结论
- NSAID是临床重要工具,但需识别高风险病例、选择特定药物、选择溃疡预防方案并治疗后监测以最小化不良事件风险。
研究设计与样本
- 由APAGE/APLAR/APSDE/APSH/APSN/PoA联合制定的多学科推荐,基于2018年1月前发表的随机对照试验和观察性研究,共纳入329篇文献合成循证推荐。
主要发现
- 治疗抵抗性高血压、高心血管风险和严重慢性肾脏病患者应尽可能避免NSAID。
- 高心血管风险患者若无法避免NSAID,优选萘普生或塞来昔布。
- 中等消化性溃疡风险者可用非选择性NSAID单药联合质子泵抑制剂,或使用选择性COX-2抑制剂;高消化性溃疡风险者需选择性COX-2抑制剂联合PPI。
- 已患高血压且使用肾素-血管紧张素系统阻断剂者,可考虑经验性加用或增加不同类别降压药。
- 多数情况下应监测血压和肾功能。
关键数值与推荐
- 开始NSAID治疗前应测量血压,在高风险病例中筛查未识别的慢性肾脏病,并调查不明原因的铁缺乏性贫血。
- 治疗抵抗性高血压、高心血管风险及严重慢性肾脏病患者尽可能避免NSAID。
- 高心血管风险者若无法避免NSAID,优选萘普生或塞来昔布。
- 中等消化性溃疡风险者:非选择性NSAID联合PPI,或选择性COX-2抑制剂;高消化性溃疡风险者:选择性COX-2抑制剂联合PPI。
- 已患高血压且使用肾素-血管紧张素系统阻断剂者,考虑经验性加用或增加不同类别降压药;多数情况监测血压和肾功能。
临床怎么用
- 处方NSAID前评估高血压、心血管、肾脏及胃肠共病风险,测量血压并筛查慢性肾脏病和铁缺乏性贫血。
- 根据心血管和消化道溃疡风险分层选择NSAID种类及是否联合PPI。
- 对已用肾素-血管紧张素系统阻断剂的高血压患者,考虑调整降压方案并监测血压和肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed medications, but they are associated with a number of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI complications. OBJECTIVE: To develop a set of multidisciplinary recommendations for the safe prescription of NSAIDs. METHODS: Randomised control trials and observational studies published before January 2018 were reviewed, with 329 papers included for the synthesis of evidence-based recommendations. RESULTS: Whenever possible, a NSAID should be avoided in patients with treatment-resistant hypertension, high risk of cardiovascular disease and severe chronic kidney disease (CKD). Before treatment with a NSAID is started, blood pressure should be measured, unrecognised CKD should be screened in high risk cases, and unexplained iron-deficiency anaemia should be investigated. For patients with high cardiovascular risk, and if NSAID treatment cannot be avoided, naproxen or celecoxib are preferred. For patients with a moderate risk of peptic ulcer disease, monotherapy with a non-selective NSAID plus a proton pump inhibitor (PPI), or a selective cyclo-oxygenase-2 (COX-2) inhibitor should be used; for those with a high risk of peptic ulcer disease, a selective COX-2 inhibitor plus PPI are needed. For patients with pre-existing hypertension receiving renin-angiotensin system blockers, empirical addition (or increase in the dose) of an antihypertensive agent of a different class should be considered. Blood pressure and renal function should be monitored in most cases. CONCLUSION: NSAIDs are a valuable armamentarium in clinical medicine, but appropriate recognition of high-risk cases, selection of a specific agent, choice of ulcer prophylaxis and monitoring after therapy are necessary to minimise the risk of adverse events.
引用
- Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut. 2020. PMID: 31937550. doi:10.1136/gutjnl-2019-319300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。